Nafarelin is a synthetic gonadotropin-releasing hormone (GnRH) agonist and peptide active pharmaceutical ingredient used in pharmaceutical formulations and endocrine research. It is a synthetic analogue of gonadotropin-releasing hormone that produces an initial stimulation of the hypothalamic-pituitary-gonadal axis followed by suppression of gonadotropin secretion with continuous administration.
Nafarelin is commonly used in pharmaceutical development as nafarelin acetate, the acetate salt of the peptide. It is associated with therapeutic applications involving hormone-dependent conditions and reproductive endocrinology.
Nafarelin is a specialized peptide pharmaceutical API used for the development and manufacture of formulations involving GnRH receptor agonist activity.
Important API quality attributes include identity, peptide purity, assay, related substances, water content, residual solvents, counter-ion content, elemental impurities and microbiological quality, as applicable to the approved specification.
CAS Number: 76932-56-4
Molecular Formula: C66H83N17O13
Molecular Weight: 1322.48 g/mol
Drug Class: Gonadotropin-Releasing Hormone Agonist
Therapeutic Class: Gonadotropin-Releasing Hormone Analogue
Therapeutic Area: Endocrinology / Reproductive Health
Molecule Type: Synthetic Peptide
Pharmaceutical Form: Nafarelin acetate
Nafarelin acts as a potent agonist of the gonadotropin-releasing hormone receptor (GnRH receptor).
Its pharmacological activity includes:
With continuous exposure, Nafarelin suppresses pituitary gonadotropin secretion, resulting in reduced ovarian or testicular steroidogenesis.
Nafarelin API is used in pharmaceutical development for:
Nafarelin is particularly relevant to reproductive endocrinology because prolonged GnRH receptor stimulation suppresses pituitary secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH).
This hormonal suppression reduces ovarian estrogen production and is an important pharmacological mechanism in the management of hormone-dependent conditions such as endometriosis.
Nafarelin is a synthetic peptide and is generally handled as a pharmaceutical peptide substance. Its physical characteristics, including appearance, water content and solid-state properties, should be controlled according to the applicable API specification.
Nafarelin is commonly used in its acetate salt form for pharmaceutical applications.
A controlled Nafarelin API manufacturing process may involve:
Typical Nafarelin API testing may include:
Store Nafarelin API in a tightly closed container under controlled pharmaceutical storage conditions, protected from excessive heat, moisture and direct light.
Because Nafarelin is a peptide API, final storage conditions should be based on validated stability data and the approved manufacturer's specification.
Nafarelin is relevant to research involving:
| Parameter | Specification |
|---|---|
| Appearance | White crystalline powder or crystals |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.5% |
| Individual Impurity | NMT 0.5% |
| Total Impurities | NMT 1.0% |
| Water Content | NMT 1.0% |